Home Events Discussions on the Who and When of Targeted Therapy in Metastatic CRC: A National Tumour Board

Discussions on the Who and When of Targeted Therapy in Metastatic CRC: A National Tumour Board


November 22 2022


7:30 pm - 9:00 pm


  • Dr Eric Chen
    Dr Eric Chen

    Dr. Eric Chen is a medical oncologist at Princess Margaret Cancer Center. He specializes in the systemic treatment of GI cancers. He participates in many clinical trials of new agents and treatment strategies in GI cancers.

  • Dr Sharlene Gill
    Dr Sharlene Gill

    Dr. Sharlene Gill is a Professor of Medicine at the University of GI malignancies at BC Cancer – Vancouver. She received a Bachelors of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 120 peer-reviewed publications and book chapters to her credit. Dr. Gill serves as the Chair of the CCTG GI Site Committee and Chair of the UBC Department of Medicine Mentoring Committee. She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists.

  • Dr. Ronald Burkes - Moderator
    Dr. Ronald Burkes - Moderator

    Dr. Ron Burkes is Professor of Medicine at The University of Toronto and staff medical oncologist at Mount Sinai Hospital/Princess Margaret Cancer Centre/University Health Network in Toronto. He was on the medical oncology training committee for the University of Toronto for 23 years and the program director for the medical oncology training program from 1996 to 2005 during which time he introduced the academic half day, the longitudinal clinic experience, the annual medical oncology research day and the staff medical oncology outstanding teaching awards. He was also the director of the Clinical Teaching Unit at the PMCC from 1999 to 2005 and established the teaching curriculum for the internal medicine residents rotating through the PMCC. He is now the Medical Oncology Mentorship Facilitator for the Division of Medical Oncology, Department of Medicine, University of Toronto.

    He has won numerous teaching awards including Departmental and University wide awards on 18 occasions, the Anderson Award in Program Development and the Hasselback Teaching Award at PMCC. He has presented at many local, provincial, national and international meetings.

    His research interests include lung and GI malignancies with a primary interest in lung, colorectal and gastric cancers. He has numerous publications including 126 peer reviewed, 154 non-peer reviewed and 2 book chapters.

  • Shaniah Leduc
    Shaniah Leduc

    Shaniah Leduc is an oncology consultant that focuses on strategic development of programs in precision oncology. As a consultant she brings 28 years of clinical nurse and research experience combined with commercial oncology experience to science-based academic programs, industry, not-for-profit organizations and Pan American Health Organization (PAHO/WHO) to support precision oncology initiatives available in Canada. Shaniah is also co-founder of OncoHelix, a Canadian-based molecular diagnostics laboratory services company that provides comprehensive genomic profiling to researchers, public health care authorities, industry sponsors and direct-pay parties.


This session will allow for sharing of challenges and solutions champions have faced in supporting enhancement of patient care through tumor agnostic treatment. The panel will discuss optimizing localized testing and treatment practices and review the journey of funding tumor agnostic therapies. The session will highlight the patient impact of tumour agnostic therapies through discussing TRK fusion cancer cases as an example to facilitate peer-to-peer knowledge translation and differentiating tumor agnostic therapies against SOC.

Co-developed with Bayer


  • Review the evolving landscape of rare alterations in GI tumors focusing on advancements in targeted and emerging therapies for metastatic CRC patients (e.g. MSI-H, HER2, NTRK, BRAF, KRAS G12C)
  • Discuss patient cases examining when to consider testing and available targeted therapies for metastatic CRC patients
  • Share physician perspectives and discuss current gaps and opportunities

Target Audience

  • Pathologists
  • Residents
  • Oncologists
  • Allied Health

CanMEDS Roles

  • Medical Expert (the integrating role)


Register for the event: Discussions on the Who and When of Targeted Therapy in Metastatic CRC: A National Tumour Board